NEW YORK, Sept. 21, 2012 /PRNewswire/ -- Aquavit
Pharmaceuticals, Inc. and Accelrys Software Inc. (NASDAQ: ACCL), a
leader in scientific innovation lifecycle management software, have
formed an alliance partnership towards the development of Aquavit's
PITO-001 and MAV-403 products. The partner agreement was
signed on September 12, 2012.
Under the terms of the partnership, Aquavit will utilize the
scientifically aware Accelrys Enterprise Platform to develop
advanced medical software for cutting-edge personalized
medicine.
"It is an exciting opportunity for both companies. As a
leading global provider of enterprise scientific informatics
software, Accelrys is the ideal partner to accelerate achievement
of Aquavit's vision. Having our products powered by the
Accelrys Enterprise Platform will support our market leading
science," said Sobin Chang,
Aquavit's Chief Executive Officer.
"We are pleased to be partnering with Aquavit Pharmaceuticals to
help accelerate the development of innovative personalized
treatments," said Sanjay Gupta, Vice
President of Corporate Development at Accelrys. "The Accelrys
Enterprise Platform will advance these initiatives by providing
unparalleled capabilities in managing end-to-end scientific
workflows to achieve better outcomes."
This partnership will be led by Thomas
S. Benjamin, Vice President of Technology at Aquavit
Pharmaceuticals. Mr. Benjamin's award winning research has
appeared in The New York Times and The Wall Street Journal.
Mr. Benjamin said, "We aim to break new ground with the
first-of-a-kind systems in our product lines. We are thrilled
to be integrating the powerful Accelrys Enterprise Platform into
the development of our next-generation medical technologies."
About Aquavit Pharmaceuticals, Inc.
Aquavit Pharmaceuticals is a multi-specialty healthcare
company focused on discovering, developing and commercializing
innovative pharmaceuticals, medical devices, and personalized
health technologies. Aquavit's business approach is enhanced
by valuable global alliances. Aquavit is developing an
innovative drug delivery system that personalizes pharmaceutical
solutions based on individual needs. The company is based in
New York City and Seoul.
About Accelrys Software, Inc.
Accelrys (NASDAQ: ACCL), a leading provider of scientific
innovation lifecycle management software, supports industries and
organizations that rely on scientific innovation to differentiate
themselves. The industry-leading Accelrys Enterprise Platform
provides a broad, flexible scientific solution optimized to
integrate the diversity of science, experimental processes and
information requirements across the research, development, process
scale-up and early manufacturing phases of product development.
By incorporating capabilities in applications for modeling
and simulation, enterprise lab management, workflow and automation,
and data management and informatics, Accelrys enables scientific
innovators to access, organize, analyze and share data in
unprecedented ways, ultimately enhancing innovation, improving
productivity and compliance, reducing costs and speeding time from
lab to market.
Accelrys solutions are used by more than 1,300 customers in the
pharmaceutical, biotechnology, energy, chemicals, aerospace,
consumer packaged goods and industrial products industries.
Headquartered in San Diego,
Calif., Accelrys employs more than 200 full-time PhD
scientists. For more information about Accelrys, visit
www.accelrys.com.
SOURCE Aquavit Pharmaceuticals, Inc.